Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial ProMIS on track to leverage new plasma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback